profit from every ₹100 of sales.
₹0₹100
OneSource Specialty Pharma
₹1,616.95+2.21% today
-6.2% in 1 year
1-year low ₹1,111.101-year high ₹1,871.50
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What OneSource Specialty Pharma sold, what it kept, and what it did with the cash.
Sales went from ₹387 million in 2023 to ₹14.2 billion in 2026, with -₹738 million of profit last year.
SalesProfit
OneSource Specialty Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| OneSource Specialty Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads OneSource Specialty Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 387 | 1,719 | 14,449 | 14,216 | |
| 183 | 1,014 | 10,098 | 9,769 | |
| -2,159 | -1,565 | 1,926 | 251 | |
| -2,614 | -1,849 | 3,731 | 3,093 | |
| -7,998 | -3,912 | -180 | -738 | |
| -69.89 | -34.18 | -1.63 | – | |
| 47.3% | 59.0% | 69.9% | 68.7% | |
| -557.6% | -91.0% | 13.3% | 1.8% | |
| -2,066.0% | -227.5% | -1.2% | -5.2% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 20,088 | 13,086 | 75,502 | 82,100 |
| Cash | 50 | 65 | 1,565 | 357 |
| Total debt | 8,642 | 5,712 | 9,424 | 15,039 |
| Total liabilities | 12,234 | 9,129 | 16,697 | 23,787 |
| 7,855 | 3,957 | 58,806 | 58,313 | |
| 114 | 114 | 110 | – | |
| -18.0% | -22.9% | 1.1% | 0.3% | |
| -101.8% | -98.9% | -0.3% | -1.3% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| -1,628 | -1,072 | -679 | 85 | |
| 440 | 638 | 1,281 | 5,691 | |
| -2,068 | -1,710 | -1,960 | -5,605 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 60 | 20 | 43 | 27 |
Valuation
- –
- –
- –
- 3.2×
- 13.0×
- –
- 64.7×
- -3.0%
- -0.4%
- –
Profitability
- 68.7%
- 1.8%
- -5.2%
- –
- 0.3%
- -9.4%
- –
- –
- –
- –
Growth
- +232.4%
- –
- –
- –
- −1.8%
Financial health
- 4.7×
- 0.26
- –
- 0.2×
- 0.99
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 36%of 952
Bottom 31%of 883
Top 1%of 870
Bottom 24%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
22No pass
Philip Fisher
47No pass
Peter Lynch
46No pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
31No pass
Questions about OneSource Specialty Pharma
Is OneSource Specialty Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the OneSource Specialty Pharma AI analysis
What does OneSource Specialty Pharma do?
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. It is in Biotechnology, based in Bengaluru, India.
Is OneSource Specialty Pharma stock halal?
Yes. OneSource Specialty Pharma passes our halal screen: its business is permitted and its debt is 8% of its market value, under the 30% limit. How we check
How has OneSource Specialty Pharma stock done over the past year?
Down 6.2% over the past twelve months, to ₹1,616.95. It traded between ₹1,111.10 and ₹1,871.50 and is 13.6% below its high.
Who are OneSource Specialty Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with OneSource Specialty Pharma's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.